S
Star Therapeutics
Developing life-changing therapies for rare diseases
About Star Therapeutics
Star Therapeutics focuses on developing life-changing therapies for rare diseases, addressing the needs of millions of patients worldwide. Operating in the biopharmaceutical sector, the company targets approximately 7,000 rare diseases, of which only about 650 have FDA-approved treatments. Star Therapeutics employs a business model centered around the development of first-in-class antibody therapeutics built on novel biology. The company generates revenue through the research, development, and eventual commercialization of these therapies. Star Therapeutics serves patients with rare diseases, healthcare providers, and the broader medical community. The company is committed to innovation and collaboration, fostering a culture of creative and forward-thinking professionals.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- South San Francisco, United States
- Employees
- 59
- Open positions
- 1
- Dealroom signal
- 86.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest May 2026
- Capital deployed
- $0
- Preferred round
- CORPORATE SPINOUT
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Sep 2025 | $125M | $500M | Undisclosed | ↗ |
| SERIES COther financing | Sep 2023 | $90M | $500M | New Leaf Venture Partners · OrbiMed · Redmile Group · Westlake Village BioPartners | ↗ |
Growth signals
Latest recorded traffic for Star Therapeutics is 3.7K monthly website visits, up 94.7% over the last three months. Star Therapeutics's team grew 11.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later13 investors entered at this stage
New Leaf Venture Partners
OrbiMed
Redmile Group
RA Capital Management
Westlake Village BioPartners
Cormorant Asset Management- CICowen Healthcare Investments
NYBC Ventures
Qatar Investment Authority
Agent Capital
Sofinnova Investments- SCSoleus Capital
Catalio Capital Management
Other known investors1 additional known investor
Electra Therapeutics
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Star Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Star Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.